Hypertension Longitudinal Data Platform in Tianjin - Trial NCT06415071

Timeline & Enrollment

Primary Outcome

Incidence rate of major adverse cardiovascular events,Prevalence of composite adervese events,Mortality rate,Prescription patterns of antihypertensive medications,Medical expenditures

Summary

Hypertension is one of the leading causes of death globally, and ranks among the top four
 risk factors for mortality and DALYs in China. However, large-scale population based
 longitudinal research data source for hypertension is lacking in China. Thus, we aimed to
 establish the first and most extensive hypertension database in China using healthcare data
 from the Tianjin city. This hypertension longitudinal data platformlinked electronic medical
 records (EMR) system 35 stores healthcare data of 1.17 million hypertension patients, from 43
 tertiary hospitals and 39 secondary hospitals, along with a public health follow-up
 management system. Data on demographics, diagnosis, drug prescription, laboratory test,
 physical examination, and cost information were collected, the median follow-up time was 4.3
 [ interquartile range (IQR): 2.7-5.8] years, and the median number of outpatient visits was
 32 (IQR: 15-64) per patient. This database can address research needs including, drug
 utilization pattern analysis, policy implementation evaluation, digital medical device
 development, and other real world evidence studies. These researches would provide robust
 evidence to assist improving patient health outcomes and healthcare system decision-making.

ICD-10 Classifications